Author:
Liu Yaqi,Wang Yixiao,Yang Yiran,Quan Yihong,Guo Mingxing
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Sung, H., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
2. Duma, N., Santana-Davila, R. & Molina, J. R. (2019). Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clinic Proceedings, 94(8), 1623–1640.
3. Choi, M., et al. (2017). Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals of Oncology, 28(1), 83–89.
4. Reck, M., Remon, J. & Hellmann, M. D. (2022). First-line immunotherapy for non-small-cell lung cancer. Journal of Clinical Oncology, 40(6), 586–597.
5. Reck, M., et al. (2016). Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. The New England Journal of Medicine, 375(19), 1823–1833.